Crohn's disease

This change may make starting Skyrizi more convenient for adults with Crohn's disease by allowing subcutaneous induction at home using an on‑body injector, rather than requiring clinic IV infusions. It also represents an...

The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...

A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...

Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.

If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...

Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...

Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...

Validated patient-reported measures help track how IBD affects daily function and well-being. A Turkish IBD-Disk gives clinicians and researchers a standardized way to measure patient-perceived disease burden and monitor...

The endoplasmic reticulum helps control cell metabolism and is implicated in conditions including metabolic disorders, cancer, and inflammatory diseases such as Crohn’s disease.

Postoperative intra-abdominal abscesses are a common, serious short-term complication after ileocecal surgery in children with Crohn’s disease and can lengthen hospital stay and delay restarting medical treatment.

This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...

An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.

This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...

This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...

An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...

Definitions of "disease burden" vary a lot, which makes it hard to compare studies or to ensure care and research address what matters most to people with Crohn's. A unified, multidimensional framework could help...

The study links common eating habits (fast food, fizzy drinks, spicy foods) with Crohn’s in this sample, which may help patients and clinicians think about dietary patterns worth discussing. It’s relevant because diet is...

This local profile highlights an IBD patient receiving scholarship support and speaking about living with Crohn’s, surgery (ostomy), and the broader immune-related effects of the disease. It may inspire patients,...

This trial tested whether an 8-week tele-CBT program can reduce IBD-related disability measured by the validated IBD Disability Index. If effective, tele-CBT could expand access to psychosocial care and improve daily...

Depression and IBD often co-occur; knowing that each can precede the other helps patients and clinicians monitor mental health and GI symptoms more proactively.

Upadacitinib is an approved oral JAK1 inhibitor with evidence for inducing and maintaining remission in moderate-to-severe Crohn's disease, including colonic-predominant disease. Patients and clinicians may consider it...

Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from Inflammatory bowel diseases.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from BMJ case reports.

This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...

A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...

If you or someone with MS is treated with rituximab (an anti‑CD20 drug), this study suggests a small increased risk of developing IBD—mostly Crohn’s disease—over time. That risk is rare but may affect treatment decisions...

A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.

Market shifts — including biosimilars, new biologics, and small-molecule drugs — can affect treatment availability, cost, and prescribing options for people with Crohn’s disease. News about acquisitions and product...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Irritable bowel syndrome, and Symptoms and flares. The original article is from msn.com.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Stem Cell Research & Therapy.

The study aims to clarify differences in visceral sensitivity and collect multiple biological samples that could help explain why some people with IBD have IBS-like symptoms. Findings could inform better symptom-targeted...

Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with...

Cure8 could only read part of this source from bvmsports.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.

People with Crohn’s disease who have had, or will have, intestinal surgery may benefit from better tools to predict early complications and endoscopic recurrence. Predictive models could help tailor follow-up and...

This study links brain structure and function differences to clinical measures and neurotransmitter systems in Crohn’s disease, which may help explain cognitive, mood, or quality-of-life effects some people with CD...

A patient describes recovering from severe Crohn’s-related malnutrition and living with an ileostomy, then regaining weight and muscle after reversal—topics many people with IBD face. The story highlights practical...

Personal stories can reduce isolation and show that people with Crohn’s disease—including high-level athletes—manage their condition and return to activities they care about. This can be encouraging and raise public...

Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...

The review evaluates a revised preprint linking GM-CSF, macrophages, and ILC-like cells in Crohn’s disease using human spatial transcriptomics and zebrafish experiments. It highlights limitations that matter because they...

Personal recovery stories can offer hope and practical ideas for people with Crohn’s who are dealing with malnutrition, body-image issues, ostomy surgery, or post-surgical recovery.

Stories like this highlight how Crohn’s can be misattributed to stress—especially for women—and the emotional, educational, and physical toll of delayed diagnosis and prolonged flares. They can help others recognise...

These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...

This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future...

New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...